4.3 Article

Effects of Darunavir/Ritonavir-Based Therapy on Metabolic and Anthropometric Parameters in Women and Men Over 48 Weeks

期刊

AIDS PATIENT CARE AND STDS
卷 25, 期 6, 页码 333-340

出版社

MARY ANN LIEBERT INC
DOI: 10.1089/apc.2010.0386

关键词

-

资金

  1. Tibotec Therapeutics
  2. Merck
  3. Schering-Plough
  4. Theratechnologies
  5. Tibotec
  6. GlaxoSmithKline
  7. Pfizer
  8. Gilead and Bristol-Myers Squibb
  9. [2K24AI056933]
  10. [K23 AI 059884]

向作者/读者索取更多资源

Gender-based differences in lipids have been noted in antiretroviral clinical trials. We present the metabolic and anthropometric data from the GRACE (Gender, Race And Clinical Experience) study by gender. Treatment-experienced adults received darunavir/ritonavir (DRV/r) 600/100mg twice daily, plus a background regimen, over 48 weeks. Fasting blood samples were obtained for lipid, glucose, and insulin measurements at baseline and at weeks 24 and 48/early discontinuation. Anthropometric measurements were taken at baseline and at weeks 12, 24, and 48/discontinuation. The Assessment of Body Change and Distress questionnaire was administered at baseline and regular intervals. Descriptive statistics as well as comparisons using a Wilcoxon rank-sum test are reported. Four hundred twenty-nine patients (women, n = 287; men, n = 142) enrolled in GRACE; 94 women (32.8%) and 33 men (23.2%) discontinued the trial. Median changes in triglycerides from baseline to week 48 were higher in men (25mg/dL versus 8mg/dL; p = 0.006); the mean change in triglycerides was higher in men than in women in all racial subgroups. Other lipid and glucose level changes were similar between genders. Anthropometric parameters increased for both genders, with larger increases in women. Patients' perceptions of body changes concurred with physical measurements. The proportion of women who were satisfied'' or very satisfied'' with their bodies increased from 45.2% to 57.8% from baseline to week 48 (p = 0.005), while the proportion of men who were satisfied'' or very satisfied'' with their bodies increased from 56.3% to 61.5% from baseline to week 48 (p = 0.317). DRV/r-based therapy was associated with small to moderate changes in metabolic parameters, and few between-gender differences were observed. Levels of self-reported, body-related distress improved for women and men over 48 weeks.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据